Figure 1.
B16/IL‐2.19 tumours exhibit delayed tumour growth and increased infiltration of CD45+ immune cells. (a) 1 × 106 tumour cells were injected intramuscularly and monitored for growth over time [B16 (dotted lines) or B16/IL‐2.19 (solid lines)]. Bars indicate standard error of the mean (n = 6 for the B16/IL‐2.19 tumours, n = 3 for B16 tumours). A second independent experiment showed the same pattern of tumour growth. B16 (b) or B16/IL‐2.19 (c) were excised on day 13 following injection, stained simultaneously for blood vessels (anti‐CD31, green) and immune cells (anti‐CD45, red), and visualized by whole mount histology. *Significant difference (P < 0·05 by Student's t‐test). Scale bar indicates 100 μm.